INTRODUCTION
Though objective EEG arousal data have indicated no significant difference between good and poor sleepers in auditory arousal threshold from sleep (Johnson, Church, Seales and Rosslter, 1979) , poor sleepers invariable report that they are "light sleepers" and are easily awakened by noises.
These poor sleepers also report difficulty in returning to sleep once awakened. Benzodiazepine sedative-hypnotics, when given to insomniacs, decrease sleep latency, awake time after sleep onset, number of body movements, and the number of nocturnal awakenings, as well as producing subjective reports of having slept more "deeply"
and "restfully". These subjective reports of "deeper" sleep occur even though EEG recordings indicate a benzodiazepine-related decrease in deep sleep, stage 4.
Are there objective data to support this subjective report of "deeper"
sleep?
If there is an increase In arousal threshold, is it related to time post drug ingestion or to stage of sleep? Is there a difference in effects on arousal threshold over the night between a hypnotic with a long acting metabolite, half-life of 24-100 hours, and a short acting benzodiazepine having a half-life of 2-3 hours? This paper will review work from our laboratory relevant to these questions.
METHOD

STUDY 1. FLURAZEPAM:
In our initial study we investigated the effects of flurazepam, 30 mg, on the auditory arousal threshold of 12 male poor sleepers (sleep onset insomniacs, mean age 21.3 + 1.0 years) selected on the basis of subjective complaints of poor sleep and EEG criteria of sleep latencies greater than 30 minutes on two consecutive screening nights (Johnson et al. 1979) . After the 2 screening nights, all 12 poor sleepers received placebo for 7 baseline nights (study nights
1-7).
Then 6 subjects received flurazepam 30 mg for 10 additional nights (study nights 8-17), and 6 continued to receive a placebo for the 10 nights. Except for the first 2 treatment nights, subjects slept in the laboratory on each study night.
Lights out was at 2200 h and wake up was at 0530 h. Medication was administered 15 minutes before lights out.
EEG sleep activity was recorded according to standard criteria (Rechtschaffen and Kales, 1968) . Only the arousal data are discussed in this paper.
An ascending series of stimulus tones was employed to obtain arousal thresholds. The stimuli were 1,000 Hz, 2 sec. tones delivered at 30 sec.
intervals, through a speaker placed 46 cm above the subject's head. Before the subject was instructed to "go to sleep", awake auditory thresholds were determined on each arousal night. approximately 5dB steps until the subject pressed a signal button three times and said, "I'm awake". Arousal thresholds were obtained during: Arousal tones were not given within 5 minutes of a body movement even when the movement did not change the sleep stage. The above schedule was followed on study nights 1 and 5 (baseline) and on nights 11 and 15 (treatment). Arousal threshold data were also collected on the first of the 3 follow-up nights, study night 18. After being aroused from sleep, the subject was told (via an intercom)
to go back to sleep. The sleep latency was the time interval between this verbal command and the first sleep spindle, K-complex (stage 2), or REM epoch.
RESULTS
The flurazepam and placebo groups did not differ significantly in arousal threshold on any of the comparisons during placebo nights. The average arousal threshold for the subjects who later received flurazepam was 76 + 16 dO, and for those who continued to receive placebo capsules, 75 + 14dB.
Since there were no between-night effects for baseline study nights 1 and 5 and for treatment study nights 11 and 15, the data were combined (i.e., mean of 1 + S and 11 + 15) to examine placebo-flurazepam group differences. No significant differences between the flurazepam and placebo groups were observed during the follow-up nights. On follow-up, the flurazepam group's arousal thresholds and sleep latencies returned to approximate baseline levels.
Study 2. TRIAZOLAN:
Triazolam is a short acting benzodiazepine hypnotic with a reported 2-3 hour half-life. In this study 20 male poor sleepers (mean age 21 + 2.37 years), were recorded during one screening night, and three consecutive placebo-baseline nights.
Following the placebo-baseline, 10 subjects continued to receive the placebo for 6 nights and 10 received triazolam, 0.5 mg, for 6 nights in a double blind paradigm. After the 6 treatment nights, all subjects received a placebo -* for 2 withdrawal nights. The selection criteria for poor sleepers and nighttime recording procedures were the same as in Study 1 (see Spinweber and Johnson, 
1982).
While the arousal procedure was similar to that in Study 1, there were some differences. The threshold for arousal from sleep was obtained on 3 recording nights: night 3 (placebo-baseline), night 6 (second treatment night), and night
(fourth treatment night).
Tones were 2 sec. long and occurred at 16 sec. The criteria which had to be met to initiate arousal procedures were similar to those of Study 1. The dB level for the highest tone presented and the latency (in minutes) from the time of awakening to the return to sleep were recorded. Within-group analyses revealed that triazolam significantly raised arousal threshold for the SWS arousal [t(9) -3.40, p ( 0.005]; it was also found that placebo group subjects became more sensitive to the tone with repeated experience and had significantly reduced arousal threshold levels during the treatment for the first, second, and third arousals.
RESULTS
Arousal
In Fig. 3 are the arousal threshold curves for both flurazepam and triazolam.
The curve for the combined placebo groups is also drawn for comparative purposes.
The differences between the two hypnotic curves were not statistically significant for any arousal. The similarity of the two curves is most striking. 
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Both hypnotics reduced the latency to return to sleep after arousal when compared to placebo (Fig. 4) . The flurazepam group had a significantly shorter mean sleep latency following the first arousal period during treatment nights. During subsequent arousals, the sleep latencies for both flurazepam and placebo groups were short and did not differ significantly from each other. For triazolam subjects, latency of return to sleep following arousal during treatment was significantly reduced for the first, second, and third arousals.
CONCLUSIONS
These data show that these two benzodiazepines do increase arousal showol an increase in sleep spindles and a decrease in delta activity.
What are the implications for those who complain of poor sleep because of noise? Most benzodiazepines will increase arousal threshold especially during the first hours of sleep and during this time period benzodiazepines are effective in assisting the return to sleep after being awakened. Our data suggest that these hypnotics would be less useful in maintaining sleep in noisy environments during the early morning hours. But once the sleep process is well established, it becomes more resistent to internal and external disruption of its night patterns. However, the results of the review by Johnson and Chernik (1982) indicate that it is unlikely that the hypnotically induced "deeper" sleep will lead to improved daytime performance. 
